Summary

Global Dupuytren’s disease market was valued at USD 4.60 billion in 2024 and is projected to experience steady growth over the forecast period, with a compound annual growth rate (CAGR) of 4.25% through 2030.
Dupuytren’s disease, also known as Dupuytren’s contracture, is a progressive condition that affects the connective tissue beneath the skin of the palm and fingers. Named after the French surgeon Baron Guillaume Dupuytren, who first described the disease in the 19th century, it primarily causes fingers to bend inward toward the palm, resulting in functional limitations.
While the exact etiology remains unclear despite ongoing research, genetic predisposition is widely acknowledged as a major contributing factor. Individuals with a family history of the condition are at significantly higher risk. Additionally, the prevalence is notably higher among people of Northern European and Scandinavian descent. Other recognized risk factors include advancing age, male gender (with men being nearly six times more likely to develop the condition), smoking, and alcohol consumption.
The disease is characterized by the formation of thickened fibrous tissue—referred to as palmar fascia—beneath the skin. Over time, this tissue contracts, pulling the fingers inward. Initial symptoms may include small lumps or nodules in the palm, which can merge into cord-like structures that lead to finger contractures. The condition most commonly affects the ring and little fingers but may involve other digits as well. These contractures can significantly impair hand function, making routine tasks such as gripping objects or shaking hands challenging.
Key Market Drivers
Rising Prevalence of Dupuytren’s Contracture
A significant factor fueling the market's growth is the increasing global prevalence of Dupuytren’s contracture. The condition affects approximately 4% of the global population, with disproportionately higher incidence rates in Northern European populations. The male-to-female ratio stands at 5.9:1, indicating a marked gender disparity.
As the number of diagnosed cases continues to rise, so does the demand for diagnostic solutions, therapeutic options, and patient care services. Incidence increases with age, with a majority of cases occurring in individuals over the age of 50. The condition affects both hands in nearly 45% of patients, with unilateral cases more commonly involving the right hand.
As global life expectancy increases—particularly in developed markets such as North America and Europe—a growing segment of the population becomes susceptible to the disease, thereby expanding the potential patient pool. This demographic trend is expected to sustain demand for accessible and effective treatment options.
Dupuytren’s contracture is significantly more prevalent among individuals of Northern European descent, with prevalence rates ranging from 4% to 39% in certain populations. Genetic predisposition further elevates the risk, particularly for individuals with a family history of the disease. As awareness of hereditary risk factors improves, early diagnosis and proactive treatment-seeking behaviors are expected to grow, contributing to market expansion.
Historically, underdiagnosis and low awareness among patients and healthcare providers have hindered treatment efforts. However, recent advancements in education, awareness campaigns, and diagnostic technologies have led to increased recognition and more timely diagnoses.
Key Market Challenges
Limited Awareness and Delayed Diagnosis
Despite the increasing prevalence of Dupuytren’s disease, limited public and clinical awareness continues to pose a challenge. Early symptoms are often mistaken for normal signs of aging or benign discomfort, leading to delayed diagnosis and missed opportunities for early intervention.
Healthcare providers play a pivotal role in improving early detection, but the relative rarity of the condition and the absence of standardized diagnostic criteria can hinder accurate recognition. Addressing this challenge requires targeted educational initiatives aimed at both medical professionals and the public to raise awareness of risk factors, symptoms, and treatment options.
Key Market Trends
Shift Toward Patient-Centric Care
The healthcare sector is undergoing a notable transformation toward patient-centric models of care, where patients play an active role in managing their treatment pathways. This shift is particularly pertinent to conditions like Dupuytren’s disease, where treatment outcomes directly influence quality of life.
As patients become more informed and engaged, there is a growing demand for treatment options that align with individual lifestyles, preferences, and goals. This evolving expectation is encouraging the development of a broader spectrum of therapeutic interventions, emphasizing personalization and improved patient experience.
Key Market Players
• Novartis AG
• Pfizer Inc.
• Bayer AG
• Nantong Jinghua Pharmaceutical Co., Ltd
• Actiza Pharmaceutical Private Limited
• Endo International plc
• Spear Pharmaceuticals
• Hikma Pharmaceuticals PLC
• Bristol-Myers Squibb
• Glaxosmithkline PLC.
Report Scope:
In this report, the Global Dupuytren’s Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Dupuytren’s Disease Market, By Type:
o Diagnosis {Physical Examination, X-ray}
o Treatment {Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others}
• Dupuytren’s Disease Market, By Disease Type:
o Type I
o Type II
o Type III
• Dupuytren’s Disease Market, By End-use:
o Hospitals
o Clinics
o Academic & Research Institute
o Others
• Dupuytren’s Disease Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Asia-Pacific
§ China
§ India
§ South Korea
§ Australia
§ Japan
o Europe
§ Germany
§ France
§ United Kingdom
§ Spain
§ Italy
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Dupuytren’s Disease Market.
Available Customizations:
Global Dupuytren’s Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Dupuytren’s Disease Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.1.2. Market Share & Forecast
5.1.3. By Type (Diagnosis (Physical Examination, X-ray), Treatment (Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others))
5.1.4. By Disease Type (Type I, Type II, Type III)
5.1.5. By End-use (Hospitals, Clinics, Academic & Research Institute, Others)
5.1.6. By Company (2024)
5.1.7. By Region
5.2. Market Map
6. North America Dupuytren’s Disease Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Disease Type
6.2.3. By End-use
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Dupuytren’s Disease Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Disease Type
6.3.1.2.3. By End-Use
6.3.2. Mexico Dupuytren’s Disease Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Disease Type
6.3.2.2.3. By End-Use
6.3.3. Canada Dupuytren’s Disease Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Disease Type
6.3.3.2.3. By End-Use
7. Europe Dupuytren’s Disease Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Disease Type
7.2.3. By End-use
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Dupuytren’s Disease Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Disease Type
7.3.1.2.3. By End-Use
7.3.2. Germany Dupuytren’s Disease Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Disease Type
7.3.2.2.3. By End-Use
7.3.3. United Kingdom Dupuytren’s Disease Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Disease Type
7.3.3.2.3. By End-Use
7.3.4. Italy Dupuytren’s Disease Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Disease Type
7.3.4.2.3. By End-Use
7.3.5. Spain Dupuytren’s Disease Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Disease Type
7.3.5.2.3. By End-Use
8. Asia-Pacific Dupuytren’s Disease Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Disease Type
8.2.3. By End-use
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Dupuytren’s Disease Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Disease Type
8.3.1.2.3. By End-Use
8.3.2. India Dupuytren’s Disease Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Disease Type
8.3.2.2.3. By End-Use
8.3.3. South Korea Dupuytren’s Disease Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Disease Type
8.3.3.2.3. By End-Use
8.3.4. Japan Dupuytren’s Disease Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Disease Type
8.3.4.2.3. By End-Use
8.3.5. Australia Dupuytren’s Disease Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Disease Type
8.3.5.2.3. By End-Use
9. South America Dupuytren’s Disease Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Disease Type
9.2.3. By End-use
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Dupuytren’s Disease Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Disease Type
9.3.1.2.3. By End-Use
9.3.2. Argentina Dupuytren’s Disease Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Disease Type
9.3.2.2.3. By End-Use
9.3.3. Colombia Dupuytren’s Disease Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Disease Type
9.3.3.2.3. By End-Use
10. Middle East and Africa Dupuytren’s Disease Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Disease Type
10.2.3. By End-use
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Dupuytren’s Disease Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Disease Type
10.3.1.2.3. By End-Use
10.3.2. Saudi Arabia Dupuytren’s Disease Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Disease Type
10.3.2.2.3. By End-Use
10.3.3. UAE Dupuytren’s Disease Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Disease Type
10.3.3.2.3. By End-Use
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. PESTLE Analysis
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. Competitive Landscape
15.1. Novartis AG
15.1.1. Business Overview
15.1.2. Product & Service Offerings
15.1.3. Recent Developments
15.1.4. Financials (If Listed)
15.1.5. Key Personnel
15.1.6. SWOT Analysis
15.2. Pfizer Inc.
15.3. Bayer AG
15.4. Nantong Jinghua Pharmaceutical Co., Ltd
15.5. Actiza Pharmaceutical Private Limited
15.6. Endo International plc
15.7. Spear Pharmaceuticals
15.8. Hikma Pharmaceuticals PLC
15.9. Bristol-Myers Squibb
15.10. Glaxosmithkline PLC
16. Strategic Recommendations
17. About Us & Disclaimer